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facilitate precision medicine, drug
safety, and regulatory science
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Lilliam Rosario2, Paul C. Howard1 and Weida Tong1, weida.tong@fda.hhs.gov
Here, we provide a concise overview of US Food and Drug Administration (FDA) drug labeling, which
details drug products, drug–drug interactions, adverse drug reactions (ADRs), and more. Labeling data
have been collected over several decades by the FDA and are an important resource for regulatory
research and decision making. However, navigating through this data is challenging. To aid such
navigation, the FDALabel database was developed, which contains a set of approximately 80 000
labeling data. The full-text searching capability of FDALabel and querying based on any combination of
specific sections, document types, market categories, market date, and other labeling information makes
it a powerful and attractive tool for a variety of applications. Here, we illustrate the utility of FDALabel
using case scenarios in pharmacogenomics biomarkers and ADR studies.
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FDA drug labels contain rich and comprehensive
information about drug products, such as dis-
ease indications, target populations, drug–drug
interactions, and ADRs. The label of a prescrip-
tion drug is prepared by manufacturers and
approved by the FDA and, thus, in its final form,
reflects the collective input from regulators, drug
manufacturers, and scientific experts. Drug-la-
beling data have been an important resource for
diverse applications, including the support for
policy development [1–4], drug discovery and
development [5,6], support for pharmacoge-
nomics applications for personalized medicine
[7–9], and scientific research [2,3,7,10–13].
Drug labeling is not static and around 400–
500 new or updated drug-labeling documents1566 www.drugdiscoverytoday.comare added every week to the current total of
approximately 80 000 structured product labels
(SPLs) (www.fda.gov/ForIndustry/
DataStandards/StructuredProductLabeling/
default.htm). Drug labeling has changed over
time because of evolving FDA regulations and
has increased in content and length, with a
standard format to guide the safe and effective
use of drugs [14] (www.fda.gov/Drugs/
GuidanceComplianceRegulatoryInformation/
Guidances/ucm065010.htm). For example, each
prescription drug labeling in the current format
is often complex, with over 20 pages of text and
tables covering a range of information about the
drug product. This rapid pace of change and the
complexity in content illustrate the need for
an advanced bioinformatics environment with1359-6446/Published by Elsevier Ltd. This is an open access article unrobust and powerful data management and
search capabilities to facilitate the application of
drug labeling information.
Here, we describe the FDALabel database
developed by the FDA as a web-based appli-
cation (www.fda.gov/ScienceResearch/
BioinformaticsTools/ucm289739.htm). The tool
allows access to the most up-to-date drug-la-
beling data and facilitates their use in regulatory
science, drug development, scientific research,
and clinical application, such as: (i) enabling easy
querying of drug information for research and
monitoring of ADRs (e.g., Boxed Warning, drug-
induced liver injury (DILI), pharmacogenomics
biomarker) to advance pharmacovigilance; (ii)
supporting research through integrating drug-
labeling data with other drug databases andder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
http://dx.doi.org/10.1016/j.drudis.2016.06.006
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information to be readily accessed by physicians,
healthcare professionals, and patients for en-
hanced healthcare; and (iv) facilitating trans-
parent knowledge exchange among the public,
pharmaceutical companies, and government
regulatory agencies. To illustrate its utility, we
provide examples of using FDALabel for phar-
macovigilance and precision medicine. Lastly, we
discuss the future direction of FDALabel devel-
opment to better support research and regula-
tory science for improved drug safety and public
health.
FDA drug labeling is a rich resource for
drug information
Structured Product Labeling (SPL)
In April 2005, the FDA published a guidance
document requiring the submission of labeling
contents in an electronic format with stan-
dardized SPL data structures (using a machine-
readable XML format and in compliance with
Health Level 7) [15,16]. Drug-labeling SPLs con-
tain diverse information about a product, such as
the carton and container labels, prescribing in-
formation, patient labeling, drug advertise-
ments, and promotional materials. The FDA
archive comprises SPLs for human drugs, bio-
logic products, animal drugs, human devices,
and human vaccines. Approximately 96%
(77 000 out of 80 000) SPLs are for human drugs,
including human prescription drugs, biologic
products, and over-the-counter drugs. In this
article, we use ‘drug labeling’ as a broad term to
define the drug information in the SPLs of the
FDA for human prescription drugs. Of note, one
prescription drug can have many drug productsTABLE 1
Summary of ‘Highlights of Prescribing Informa
and biological products.
Title 
Limitations Statement 
Product Names 
Initial U.S. Approval 
Boxed Warning 
Recent Major Changes 
Indications and Usage 
Dosage and Administration 
Dosage Forms and Strengths 
Contraindications 
Warnings and Precautions 
Adverse Reactions 
Drug Interactions 
Use in Specific Populations because of the differences in regulatory appli-
cation, dosage forms, routes of administration,
and manufacturers. Although there are only
approximately 1600 human prescription drugs,
there are approximately 31 000 SPLs.
Physician Labeling Rule (PLR)
In 2006, FDA issued the final regulation
‘Requirements on Content and Format of La-
beling for Human Prescription Drug and Bio-
logical Products’ (www.fda.gov/Drugs/
GuidanceComplianceRegulatoryInformation/
LawsActsandRules/ucm084159.htm), which is
also known as the ‘Physician Labeling Rule (PLR)’
as described in 21 CFR 201.56 and 201.57. Its
central goal is to provide structured labeling
information that is easy to access, read, and use
by both the FDA and the public. Specific
requirements were added, such as ‘Highlights of
Prescribing Information’, ‘Table of Contents’, and
‘Reorders and Reorganizes’ sections. The revi-
sions were mandatory for new drug labeling as
well as for drugs that have been on the market
up to 5 years before the effective date of the PLR
(June 30, 2006). Consequently, the PLR enhances
the consistency in drug labeling and makes it a
valuable resource for drug review, development,
and research.
As summarized in Table 1, ‘Highlights of Pre-
scribing Information’ is a half-page summary of
the essential safety and efficacy information for
approved human prescription drug and biologi-
cal products. By contrast, full prescribing infor-
mation has a total of 17 labeling sections with
more detailed content compared with the
‘Highlights’. The additional sections include Drug
Abuse and Dependence (Section 9), Over Dosagetion’: the essential safety and efficacy informa
Notes
For example, These highlights do not 
needed to use ZIAGEN safely and effe
For example, ZIAGEN (abacavir) tablet
For example, Initial US approval: 1998
Commonly known as a black box war
The month and year the change was 
Concise Summary of Labeling Section
Concise Summary of Labeling Section
Concise Summary of Labeling Section
Concise Summary of Labeling Section
Concise Summary of Labeling Section
Concise Summary of Labeling Section
Concise Summary of Labeling Section
Concise Summary of Labeling Section(Section 10), Clinical Pharmacology (Section 12),
Nonclinical Toxicology (Section 13), Clinical
Studies (Section 14), and Patient Counseling In-
formation (Section 17). The information in each
section is structured and specified for certain
drug information. Of note, patients receive the
prescription drug information with limited in-
formation from the Full Prescribing Information
(FPI) specified for patient (Medication Guides).
Pharmacogenomics data
In January 2013, the guidance for industry on
‘Clinical Pharmacogenomics’ information prep-
aration for labeling was released [14] (http://
www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/
Guidances/UCM337169.pdf ). A new subsection,
Pharmacogenomics, was added under Clinical
Pharmacology (Section 12). The guidance doc-
ument indicates that, ‘If applicable, a ‘Pharma-
cogenomics’ subsection should be included in
the CLINICAL PHARMACOLOGY section 12 (e.g.,
as ‘12.5 Pharmacogenomics’) of the prescribing
information (PI) and should include clinically
relevant data or information on the effect of
genetic variations affecting drug therapy’. Re-
cently, many pharmacogenomics biomarkers
have been included in drug labeling (e.g., the
drugs warfarin, boceprevir, Nuedexta1, Bro-
vana1, and pantoprazole) [8], which allows
clinicians to apply these drugs to the specific
populations who are most likely to benefit from
precision medicine [8,9]. The pharmacoge-
nomics biomarkers found in drug labeling can be
categorized as: (i) involved in drug metabolism
variability (e.g., CYP enzymes) among individu-
als; (ii) associated with increased risk for adversetion for approved human prescription drug
include all the information
ctively. See full prescribing information for ZIAGEN
s, for oral use
ning
made
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BOX 1
Example applications using drug labeling data
Drug interactions
Drug labeling has a specific section to summarize the findings relating to drug–drug
interactions and their associated adverse events in drug application. Some specific
questions can be queried against the labeling data, such as which drugs used to treat HIV (in
the Drug Indications and Usage Section) are known to interact with methadone and which
drugs will interact with disulfiram (in the Drug Interactions Section).
Drug classification
There are several ways to classify drugs; each one has its intended application (e.g., clinical
application, mechanistic study, chemical structure, etc.). For example, which drugs share the
same pharmacologic class, such as kinase inhibitors, HIV protease inhibitors, or beta-
adrenergic blockers, and so on. The drug-labeling indexing provides classification based on
Established Pharmacologic Class (EPC), Mode-of-Action (MoA), Physiologic Effect (PE), and
Chemical Ingredient by structure (CI). These classification schemes facilitate the study of
drug class effect and evidence-based justification for making a labeling change to a drug
class during the review process.
Adverse events
Three sections (Boxed Warning, Warnings and Precautions, and Adverse Events) summarize
drug-related adverse events, which have been widely applied in pharmacovigilance and
drug safety research. While the standard vocabulary to describe adverse events is not
mandatory, most terminologies for adverse events are implemented with certain standard
terminology (such as SNOMED and MedDRA), which facilitates the study of the adverse
events data in the drug labeling.
Precision medicine
A large number of pharmacogenomics biomarkers are included in drug labeling. These
biomarkers are likely to impact the effectiveness and adverse events for patients from
specified subpopulations taking the drugs. Thus, the information facilitates the identification
of new trends and frequency of genetic variability associated with increased risks to public
health, which is an important goal in precision medicine.
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describing the mechanism of action of the drug
(e.g., CD30), which likely impacts the effect of the
drug on specified patients (www.fda.gov/drugs/
scienceresearch/researchareas/
pharmacogenetics/ucm083378.htm).
In summary, the drug labeling contains rich
information from clinical studies, nonclinical
studies, and postmarketing experiences regarding
ADRs for pharmacovigilance and pharmacoge-
nomics. At the FDA, drug-labeling development
has been a crucial element in the drug review
process. Its content can also support diverse re-
search needs. Box 1 summarizes some of the key
applications using the drug-labeling data.
FDALabel database
The FDALabel database contains over 80 000
full-text SPLs. The source of FDALabel data is the
SPLs of the FDA archived in the FDA Online
Labeling Repository (http://labels.fda.gov/) and
DailyMed (http://dailymed.nlm.nih.gov/
dailymed/index.cfm). FDALabel was implemen-
ted as a secure three-tier platform with an Oracle
database and is updated quarterly. The database
can be accessed through a web-based applica-
tion. The tool has a simple query that can be
intuitively performed (e.g., full-text search,
product or generic name search in version 1.0).
Importantly, the advanced query functions are1568 www.drugdiscoverytoday.comimplemented to perform a range of queries for,
individually or in combination: (i) presence of, or
text within, specific sections of the prescribing
information; (ii) document types (e.g., Human Rx,
Human OTC, Vaccine); (iii) marketing categories
(e.g., NDA, ANDA, BLA); (iv) SPL identifiers (e.g.,
Product NDC Codes and SETIDs); and (v) Market
start/end date. In addition, the search summary
results can be downloaded as a spreadsheet that
links to the original SPLs.
Of note, DailyMed is a widely used resource for
drug labeling and provides SPL data. However,
many unique functions (e.g., the full-text
searching capability and querying based on any
combination of specific drug fields and sections)
are available in FDALabel and, thus, make it a
more powerful, user friendly, and attractive tool
(see Table S1 in the supplemental information
online for comparisons between FDALabel and
DailyMed). For example, we searched for the
keywords ‘acute liver failure’ in ‘Full Text Query’,
which resulted in 757 labeling hits. We also
searched the same keywords within Boxed
Warning using ‘Section Present’, which resulted
in 556 labeling hits. In addition, we also added
NDA as filter from ‘Marketing Categories’, with
the same two queries resulting in 53 hits and 23
hits, respectively. Thus, a large number of
duplications in drug labeling can be easily re-
moved by using NDA as a filter in FDALabel,which is not readily available in DailyMed. The
unique functions of FDALabel database enable
the drug-labeling content to be more easily
accessed by researchers for ADR study, FDA
medical officers for drug review, pharmaceutical
companies for drug development and reposi-
tioning, and physicians and consumers for drug
safety information. Google Analytics has shown
that the number of users has increased greatly
since the database opened for public access in
2012 (Fig. S1 in the supplemental information
online).
FDALabel use cases
Pharmacogenomics biomarkers
Some pharmacogenomics biomarkers are asso-
ciated with ADRs. We queried five ADR-related
biomarkers (i.e., G6PD, TPMT, DPD, HLA-B*1502,
and HLA-B* 5701) in FDALabel (Table S2 in the
supplemental information online) and built a
network visualization of the drug–ADR relations
via these biomarkers (Fig. 1). The results illus-
trated that patients who carry the HLA-B*5701
allele are at high risk for experiencing a hyper-
sensitivity reaction (HR) to abacavir, while
patients who carry the HLA-B*1502 allele are at a
high risk of HR to carbamazepine, which could
lead to Steven–Johnson syndrome, a severe ADR
mentioned in the Box Warning section [17,18].
ADR study using MedDRA standard
Medical Dictionary for Regulatory Activities
(MedRA; www.meddra.org/) is widely used in the
USA, European Union, and Japan for ADR
reporting. Extracting MedDRA standard terms
from drug labeling will allow researchers, regu-
lators, and healthcare professionals to better
understand the trends and frequencies of ad-
verse events for drugs in the current markets [6].
There are five term levels in MedDRA, from
lowest to highest: LLT (Low-Level Term), PT
(Preferred Term), HLT (High-Level Term), HLGT
(High-Level Group Term), and SOT (System Or-
gan Class), with PTs the most commonly used for
ADR study. Our mapping showed that, out of a
total of 74 229 MedDRA (version 18.0) LLTs,
11 847 LLTs have appeared in FDA-approved
prescription drug labeling, which, in turn, iden-
tified 6161 PTs (out of total of 21 345 PTs in
MedDRA). The top ten labeling sections that
contain the most PTs are plotted by counts
(Fig. 2). Not surprisingly, the Adverse Reactions
section contained the most PTs (4444), followed
by Precautions (2656), Warnings and Precautions
(2550), Clinical Study (2475), Indications and
Usage (2460), Clinic Pharmacology (2161), and
Warnings (2134). Of note, the Precautions sec-
tion and the Warnings section in non-PLR format
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FIGURE 1
Five selected pharmacogenomics biomarkers and their associated adverse effects and drugs. A network visualization illustrates the relation among drugs (blue),
biomarkers (green), and associated adverse effects (red) based on the information retrieved from FDALabel. For example, patients who carry the HLA-B*1502 allele
are at a high risk for experiencing a hypersensitivity reaction (HR: such as Stevens–Johnson syndrome) to carbamazepine.
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Precautions section in the new drug-labeling
format in PLRs.
Drug-induced liver injury study
We utilized drug-labeling data to study DILI [17],
drug safety [19], and drug repositioning [5]. For
example, we developed a systematic annotation
method using drug-labeling information to an-5000
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Distribution of MedDRA preferred terms (PT) in differennotate the potential of a drug for DILI. Specifi-
cally, a combination of keywords about DILI,
which reflected not only different types, but also
various severity levels of DILI, was used to search
against the drug-labeling database. The study
enabled the relevant DILI information to be
extracted from three labeling sections (Boxed
Warning, Warnings and Precautions, and Adverse
Reactions) with a DILI classification scheme to44
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t labeling sections. The top ten sections are listed.define a benchmark DILI data set that is widely
used as a model in DILI study [20,21].
Concluding remarks and future
perspectives
FDA drug labeling has accumulated over the
past 40 years or so [since the Federal Register of
June 26, 1979 (44 FR 37434)] and is an integral
part of the FDA review process. In addition,
many guidance documents have been issued
by the FDA to facilitate its application, such as
for drug discovery and development. Similar
labeling resources have also been developed
around the world, such as in Europe and Japan.
Given the recent implementation of data
standards and rapid advancement of informa-
tion technology, drug-labeling data has grown
tremendously, truly becoming regulatory big
data for knowledge discovery and drug-centric
research to improve public health. To fully
utilize these regulatory big data, powerful tools
and databases with flexible functions are cru-
cial. FDALabel is one such tool, developed by
the FDA to specifically support regulatory sci-
ence. The tool fills the gap in the FDA where
large amounts of the drug information are
available, but few tools are available to take
advantage of it.www.drugdiscoverytoday.com 1569
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related to drugs within the FDA. Furthermore,
many drug-centric databases and data stan-
dards have also been developed by the research
community. However, these databases, includ-
ing those developed by the FDA, are often not
easily available to inform the FDA review pro-
cess and drug safety research. We intend to
address this challenge by expanding FDALabel
by integrating it with multiple disparate data-
base contents to provide comprehensive access
to drug-related information. The expanded
FDALabel will make the data accessible in a way
that is useful and focused on the question asked
by reviewers and researches to discover
knowledge and fill the knowledge gap. At the
time of writing, the information and databases
currently being evaluated for integration were:
(i) Drugs@FDA, which provides drug approval
history; (ii) FDA Orange Book, containing pub-
lications for approved drug products with
Therapeutic Equivalence Evaluations, which
provides patent related information; (iii) ‘Phar-
macological Class Indexing’ from SPLs, which
will enable searches for ADRs across drug class
products. Drugs from the same pharmacologi-
cal class often share similar efficacy and safety
profiles; (iv) MedDRA, which provides standard
terminology for international clinical results
used by regulatory authorities in the pharma-
ceutical industry; (5) RxNorm, which provides
normalized names for clinical drugs and links
their names to many of the drug vocabularies
and databases commonly used; (vi) FAERS,
which the Adverse Event Reporting System of
the FDA for drug products; and (vii) Substance
Registration System-Unique Ingredient Identi-
fier (SRS-UNII), which provides unique chemical
substance information and structure for drugs.
Furthermore, we will implement more options
for flexible access to this integrated information,
such as searches for drug class, chemical
structure, topic, and so on. Our ultimate goal is
to provide publicly available, rich, accurate, and
complete information that facilitates transpar-
ent knowledge exchange among the public,
pharmaceutical companies, and government
regulatory agencies.
Disclaimer
FDALabel database is not compatible with In-
ternet Explorer. We suggest that users use Firefox
or Google Chrome as Internet browsers. FDA-
Label is not a diagnostic tool and is not intended1570 www.drugdiscoverytoday.comto inform regarding choice of medicines or
therapies for medical conditions. The views
presented in this article do not necessarily reflect
current or future opinion or policy of the U.S.
Food and Drug Administration. Any mention of
commercial products is for clarification and not
intended as endorsement.
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